What NeuroPace (NPCE) Said on Its Q3 Earnings Call
NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.
How this was made

The 30-second read
Why it matters
The guidance cut is the primary market‑moving element; other operational updates are secondary.
Market read
Guidance reduction is a fresh, material fact for investors; it likely triggers a sell‑side reaction.
What to watch
Potential upside from upcoming FDA submissions for IGE indication and Remote Care feature could mitigate revenue concerns.
Background
NeuroPace reported Q3 results, improved margins, and provided updated 2026 guidance while outlining FDA submission plans for new indications.
Ticker impact
NeuroPace cut its 2026 revenue guidance to $91‑$92M, down from $99.5‑$101.5M, and lowered operating expense outlook.
likely downside as market prices in lower revenue expectations
Revenue guidance is a material metric; the cut is a fresh disclosure that directly affects valuation.
Market effects
May weigh on med‑tech and neuro‑stimulation peers as demand outlook softens.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche neuro‑tech segment.
Counterpoint
If the guidance cut reflects temporary delays rather than long‑term demand, the stock could rebound on a short‑term oversell.
Key entities
- companyNeuroPace, Inc.
Medical technology firm developing the RNS System for drug‑resistant epilepsy.

